My research interest is to improve treatment of patients with prostate cancer and sarcoma by studying better ways to classify and identify disease, and by improving the way radiotherapy is given alone or in combination with other treatments.
Our research is aimed at improving the therapeutic ratio in patients receiving radiotherapy for prostate cancer and other genitourinary (GU) malignancies. Our research focus is to improve the therapeutic ratio for prostate cancer by developing image-guided intensity-modulated radiotherapy techniques (IG-IMRT) that more precisely deliver radiotherapy to the target and away from critical normal tissues. We work in close collaboration with others in the GU group who are investigating novel imaging techniques intended to identify more precisely the gross tumour volume (GTV) for treatment planning, and to evaluate response and identify new factors that are predictive of radiation response. We are evaluating acute and late toxicities of treatment and developing dose-volume models to predict toxicity.